Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 14/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24818952 | 1.00 | VSIR (0.41) | VSIRKCNH2CYP2D6GRIN2BPDCD1 | |
| SCHEMBL30153084 | 0.97 | VSIR (0.40) | VSIRKCNH2CYP2D6GRIN2BPDCD1 | |
| SCHEMBL30152568 | 0.97 | VSIR (0.40) | VSIRKCNH2CYP2D6GRIN2BPDCD1 | |
| SCHEMBL24820273 | 0.97 | VSIR (0.40) | VSIRKCNH2CYP2D6GRIN2BPDCD1 | |
| SCHEMBL24820155 | 0.97 | VSIR (0.40) | VSIRKCNH2CYP2D6GRIN2BPDCD1 | |
| SCHEMBL24818735 | 0.94 | VSIR (0.40) | VSIRKCNH2CYP2D6GRIN2BPDCD1 | |
| SCHEMBL24819925 | 0.91 | VSIR (0.40) | VSIRKCNH2PDCD1CD274 | |
| SCHEMBL30152858 | 0.91 | VSIR (0.40) | VSIRKCNH2PDCD1CD274 | |
| SCHEMBL24818944 | 0.90 | ATM (0.40) | VSIRKCNH2PDCD1CD274 | |
| SCHEMBL24821759 | 0.90 | ATM (0.40) | VSIRKCNH2PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | VSIR 1674/4885KCNH2 4831/4885CYP2D6 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.